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EDITORIAL
Quantiﬁcation  of  hepatic  fat:  Which
reference  should  be  the  reference?
Steatosis  is  present  in  a wide  spectrum  of  liver  diseases  [1].  Active  experimental  and
clinical  research  has  focused  on  the  recognition  of  nonalcoholic  fatty  liver  disease  (NAFLD)
because  its  prevalence  is  increasing  in  adult  and  pediatric  population,  and  it  is  expected  to
become  the  ﬁrst  cause  of  chronic  liver  disease  in  the  upcoming  decade  [2,3]. Steatosis  has
been  shown  to  be  associated  with  myriad  conditions,  including  cardiovascular  diseases,
diabetes  mellitus,  and  metabolic  syndrome.  It  also  conveys  a  higher  morbidity  rate  after
major  liver  surgery.  Therefore,  assessment  and  quantiﬁcation  of  liver  fat  content  are  very
important.  Until  very  recently,  liver  biopsy  has  been  considered  as  the  reference  method  to
accurately  diagnose  hepatic  steatosis.  Nevertheless,  it  is  invasive  and  suffers  from  several
limitations,  mainly  sample  bias.
Over  the  past  decade  magnetic  resonance  imaging  (MRI)  has  been  increasingly  used
as  a  non-invasive  alternative  for  the  determination  of  hepatic  fat  content.  Historically,
magnetic  resonance  spectroscopy  (MRS)  has  been  considered  as  the  reference  imaging
method.  More  recently,  chemical  shift-based  sequences  have  been  developed,  and  multi-
echo  sequences  have  become  the  new  gold  standard  for  quantiﬁcation  of  fat,  either  with
complex-  or  magnitude-based  techniques  [4,5]. As  a  consequence,  we  now  face  several
competing  reference  techniques,  and  the  question  of  which  should  be  consensually  used
in  daily  practice  remains  to  be  answered  deﬁnitely.
To  address  this  question,  Leiber  et  al.  have  chosen  to  adopt  an  original  point  of  view,
for  three  reasons  [6]. First,  to  properly  compare  conventional  histological  analysis  and
MR  imaging,  they  used  a  third  and  independent  technique,  the  intrahepatic  triglyceride
content,  assessed  by  biochemical  analysis.  This  technique  gives  the  true  liver  triglyceride
content,  from  a  biochemical  point  of  view.  Leiber  et  al.  have  shown  that  magnitude-
based  MR  imaging  provided  the  best  correlation  with  the  intrahepatic  triglyceride  content.
Indeed,  the  classical  visual  histological  evaluation  of  steatosis  measures  the  percentage
of  hepatocytes  containing  lipid  vacuoles,  and  not  the  liver  fat  content  per  se.
Second,  they  used  an  animal  model  to  demonstrate  the  temporal  evolution  of  liver  fat
accumulation.  Rodent  models  have  been  widely  used  to  monitor  both  the  dynamics  of  fat
accumulation  during  obesity  and  anti-obesity  interventions.  Yet  side-by-side  comparison
of  MRI/MRS  and  histology  for  fat  quantiﬁcation  had  been  poorly  studied  in  such  a  dynamic
way.  Leiber  et  al.  have  shown  that  MRI  quantiﬁcation  followed  closely  the  progressive
accumulation  of  fat,  while  conventional  histological  analysis  resulted  in  a  ‘‘all  or  noth-
ing’’  result.  This  illustrates  the  inability  of  conventional  histological  analysis  to  precisely
measure  small  variations  of  intrahepatic  lipid  associated  with  the  therapeutic  effect  of
potential  anti-steatotic  drugs  that  are  currently  being  developed.
Third  and  ﬁnally,  they  have  included  the  histological  quantiﬁcation  of  the  area  of
steatosis  (AOS).  This  technique  mirrors  the  collagen  proportionate  area  developed  for
the  evaluation  of  liver  ﬁbrosis.  It  shows  the  progressive  effort  of  pathologists  toward  more
reproducible  and  quantitative  approaches.  However  Leiber  et  al.  observed  that  AOS  tended
to  successively  under-  and  overestimate  the  true  fat  content  of  the  liver  [6].
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Overall,  Leiber  et  al.  clearly  demonstrate  the  superior-
ty  of  magnitude-based  chemical  shift  MR  techniques  over
oth  conventional  and  quantitative  histological  analysis  for
he  quantiﬁcation  and  temporal  follow-up  of  the  liver  fat
ontent.  As  a  matter  of  fact,  and  more  importantly,  the  arti-
le  from  Leiber  et  al.  highlights  an  important  issue,  which  is
ow  accurately  should  we  quantify  liver  fat  content?  Should
e  stick  to  the  classical  pathologic  classiﬁcation  [7]?  Should
e  precisely  measure  liver  fat  content?  There  is  a  trend  to
o  so  as  several  ongoing  trials  aim  to  evaluate  the  efﬁcacy  of
arious  anti-steatotic  drugs.  This  will  also  be  important  if  the
elationship  between  the  amount  of  fat  and  the  progression
o  NASH  is  to  be  clariﬁed.  We  are  currently  in  a  transition
eriod.  We  used  to  need  only  simple  information  about  the
resence  or  absence  of  fat.  We  progressively  understand,
s  the  obesity  and  metabolic  syndrome  epidemic  progres-
ively  expands  geographically  and  demographically,  that  this
s  not  enough  anymore,  and  that  we  need  to  be  more  pre-
ise  in  order  not  only  to  assess  the  presence  of  fat,  but  more
mportantly  to  monitor  its  evolution  over  time,  and  to  assess
ts  molecular  composition  [8].  Habits  are  hard  to  break.  But
ad  habits  are  easier  to  abandon  today  than  tomorrow,  says
he  proverb.
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